Exchange: NASDAQ·Updated 04:10 PM EST
MDWD logo

MDWD MediWound Ltd

$13.59
$0.05
(0.37%)
Today
Closed $13.59
$0.00
(0.00%)
After Hours
Reported EarningsNov 12
Mkt Cap$174.81M
Vol187,835.00

About MDWD

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
41

Bearish Sentiment

How do you feel about MDWD?

okeydokey_artichokey
$MDWD Wondering if they couldn't develop a more dilute version of EscharEX for cosmetic exfoliation??
1
gerson999
$MDWD the math could add to a buy out price next year. At the end of november the remaining mdwd warrants expire, if the stock remains below 13.475. If the company gets a buy out bid by the end of next year, that will mean there will be 2.13 million less shares outstanding. The expiration would increase each remaining shareholder's proportional ownership by approximately 13.50%.
2
Logic102
$MDWD Very underfollowed by investors but certainly NOT underfollowed by large companies in the Wound Care industry. The stock doesn't move a lot until one day the takeover announcement happens.
2
okeydokey_artichokey
$MDWD if one has any interest in this company Pubmed search Nexobrid. Many positive clinical trials.
1
Logic102
$MDWD 12.50 per share was the price on hopefully the last dilution necessary before a deal or a buyout. The future is bright with best-in-class disruptive products in both the burn debridement and the wound care space (pending the final P3 results in Wound Care--highly likely to succeed IMO). Several much larger companies in this space such as Smith and Nephew have relationships with MDWD.
1
JohnPDaly
$MDWD MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026 Leading wound care experts to discuss Phase II clinical evidence, the pivotal Phase III VALUE study, and the estimated $1.05 billion U.S. annual peak sales potential
BioGem
$MDWD This should be a short. Several negatives, yet too overvalued on P/S or EV/S ratios. -Huge miss on the top line. No matter how management manipulates the info, they have no clue as to what will happen to their government related projects. -Continues with hefty operating losses and cash burn, all worse YOY. -Cash is running out quickly, so they resort to stock dilution. -Short interest is high = consensus of poor stock. -None of the prestigious biotech funds is invested.
TheGodsMustBeCrazy
Yes. $MDWD CEO bought shares on nov 10th. So did two other insiders (two directors). They paid 13.475 per share. That's very bullish.
StocktwitsEarnings
$MDWD Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.65 down -170.83% YoY • Reported revenue of $3.57M down -34.25% YoY • MediWound's 2026 revenue outlook depends on U.S. government funding discussions; a substantial portion of anticipated revenue relates to planned U.S. manufacturing development services, with timing and recognition uncertain.
JohnPDaly
$MDWD MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12th at 8:30 a.m. Eastern Time

Advertisement|Remove ads.